# Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

Source: https://onco.cc/trials/nct05317858/  
OnCo record `nct05317858` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pembrolizumab, Atezolizumab, Cemiplimab in non-small-cell lung cancer and small-cell lung cancer, run by InSightec, now recruiting.

## Summary

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets is a phase 3 interventional study registered as NCT05317858 by InSightec, with 30 participants planned, started 2022-08-12 and due to reach its primary completion in 2027-06-01. Interventions recorded: Blood Brain Barrier Opening - Oncology, Pembrolizumab, Atezolizumab, Cemiplimab, Nivolumab. Conditions listed: Brain Tumor, Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05317858
- Phase: 3
- Setting: A Randomized Pivotal Study Assessing the Safety and Efficacy of Targeted Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound During the Standard of Care Treatment of Brain Metastases of Non-small Cell Lung Cancer (NSCLC) Origin
- Sponsor: InSightec
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT05317858: https://clinicaltrials.gov/study/NCT05317858

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Insightec](https://onco.cc/companies/insightec/)

---
JSON: https://onco.cc/api/v1/entities/nct05317858.json